Host: The Japanese Society of Toxicology
Name : The 49th Annual Meeting of the Japanese Society of Toxicology
Date : June 30, 2022 - July 02, 2022
Cytokine release syndrome (CRS) is a typical adverse effect caused by an infusion of therapeutic antibodies. CRS may lead to interruption or delay in the development of new therapeutic antibodies and therefore preventing or reducing the CRS risk is an important issue. It is difficult to predict the CRS risk using animals since the expression of target molecules and FcγRs in animals are different from those in humans. Therefore, cytokine release assay using human peripheral blood mononuclear cells or whole blood is widely used for risk assessment.
In this presentation, we will introduce a case of therapeutic antibody where elevated cytokines were observed in the clinical trial, and present the nonclinical risk evaluation and investigation of underlying mechanisms conducted using human peripheral blood mononuclear cells and whole blood.
